Kaken Pharma 
Welcome,         Profile    Billing    Logout  
 14 Products   11 Diseases  14 Products   46 Trials   2075 News 
68 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fyarro (nanoparticle albumin-bound rapamycin) / Kaken Pharma
NCT03463265: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Completed
2
62
US
nab-sirolimus, nab-sirolimus + temozolomide, temozolomide, nab-sirolimus + bevacizumab, bevacizumab, nab-sirolimus + lomustine, lomustine (CCNU), nab-sirolimus + marizomib (MRZ), marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy, radiation
Aadi Bioscience, Inc.
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
08/22
08/22
NARETO, NCT06494150: Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Recruiting
2
37
US
nab-Sirolimus, Fyarro, Fulvestrant, Faslodex
University of Oklahoma, Aadi Bioscience, Inc.
Low Grade Ovarian Serous Adenocarcinoma
08/27
09/29
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
EEC-201, NCT05997017: Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Recruiting
2
29
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
03/25
10/26
NET-202, NCT05997056: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting
2
21
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
05/25
12/25
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Terminated
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
07/24
NCT02975882: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Completed
1
33
US
Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus Albumin-bound Nanoparticles, ABI 009, ABI-009, ABI009, Albumin-bound Sirolimus, Fyarro, Nab-Rapamycin, Nab-sirolimus, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Sirolimus, Sirolimus Albumin-bound Particles, Sirolimus Protein-bound Particles, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
03/22
12/24
RaSuRE, NCT03646240: ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy

Completed
1
14
US
ABI-009
Seattle Children's Hospital, Aadi Bioscience, Inc.
Epilepsy Intractable
08/22
12/22
NCT05661461: Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Recruiting
1
28
US
nab-sirolimus, ABI-009, nab-rapamycin, albumin-bound rapamycin
Aadi Bioscience, Inc.
Tumor, Solid, Tumor, Advanced Solid Tumor
04/25
04/25
NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Recruiting
1
12
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus
M.D. Anderson Cancer Center, Aadi Bioscience
Leiomyosarcoma, Soft-tissue Sarcomas
02/29
02/31
KRYSTAL -19, NCT05840510: Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Terminated
1
6
US
Adagrasib, MRTX849, Krazati, nab-Sirolimus, ABI -009, Fyarro
Mirati Therapeutics Inc., Aadi Bioscience, Inc.
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
12/24
12/24
Resunab (lenabasum) / Corbus Pharma, Kaken Pharma
ACTRN12620000712909: A Study of the Pharmacokinetics and Safety of a Single Dose of Lenabasum in Subjects with Hepatic Impairment Compared with Matched Healthy Controls

Not yet recruiting
1
32
 
Corbus Pharmaceuticals Inc, Corbus Pharmaceuticals
Hepatic impairment, Liver cirrhosis
 
 
Livdelzi (seladelpar) / Gilead
2020-005198-29: A study to evaluate the safety and tolerability of seladelpar in subjectswith primary biliary cholangitis

Ongoing
3/4
500
Europe, RoW
Seladelpar, MBX-8025, Capsule, hard
CymaBay Therapeutics, Inc., CymaBay Therapeutics, Inc.
Primary Biliary Cholangitis, A long-term liver disease in which the bile ducts in the liver becomedamaged. This gradually leads to a build-up of bile in the liver, which candamage it and eventually lead to scarring., Body processes [G] - Immune system processes [G12]
 
 
RESPONSE, NCT04620733 / 2020-004348-27: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Completed
3
193
Europe, Canada, US, RoW
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
CymaBay Therapeutics, Inc.
Primary Biliary Cholangitis
08/23
08/23
NCT03301506 / 2017-003910-16: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
500
Europe, Canada, US, RoW
Seladelpar 5 mg Capsule, MBX-8025, Livdelzi®, Seladelpar 10 mg Capsule
Gilead Sciences
Primary Biliary Cirrhosis
11/28
11/28
IDEAL, NCT06060665: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
90
Canada, US
Seladelpar 10 mg, Placebo
Gilead Sciences
Primary Biliary Cholangitis
06/26
06/26
AFFIRM, NCT06051617: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Recruiting
3
318
Canada, US, RoW
Seladelpar, Livdelzi®, Placebo
Gilead Sciences
Primary Biliary Cholangitis
08/30
08/30
2019-001760-30: The aim of this study is to assess the safety, tolerability and efficacy of seladelpar in subjects with Primary Sclerosing Cholangitis (PSC)

Not yet recruiting
2
100
Europe
Seladelpar, MBX-8025, Capsule
CymaBay Therapeutics, CymaBay Therapeutics
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease that is characterized by diffuse inflammation and fibrosis of the bile ducts. The intra and/or extrahepatic bile ducts can be affected with ongoing ductal destruction leading to cholestasis, advanced fibrosis, and cirrhosis. Disease progression will eventually lead to liver failure with its consequent complications such as portal hypertension and increased risk of malignancy, including HCC and cholangiocarcinoma., Disease of the liver, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04950764: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Completed
1
24
Europe, US, RoW
Seladelpar 10 mg, Livdelzi®, Seladelpar 10 mg or less
Gilead Sciences
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
02/25
02/25
Ekterly (sebetralstat) / KalVista
KONFIDENT, NCT05259917 / 2021-001226-21: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed
3
136
Europe, Canada, Japan, US, RoW
Placebo, KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
12/23
12/23
KONFIDENT-KID, NCT06467084: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Recruiting
3
36
Europe, Canada, Japan, US, RoW
KVD900 75 mg, KVD900 150 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
08/27
08/27
NCT05511922: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting
3
12
Europe, Canada, Japan, US, RoW
KVD900 600 mg, Drug: KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
06/26
06/26
KONFIDENT-S, NCT05505916 / 2021-001176-42: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active, not recruiting
3
145
Europe, Canada, Japan, US, RoW
KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd., KalVista Pharmaceuticals Ltd
Hereditary Angioedema
06/26
06/26
NCT06628713: Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Available
N/A
US
Sebetralstat, KVD900
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
 
 
tildacerfont (SPR001) / Spruce Biosciences
NCT05370521: A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Completed
2
27
US
Tildacerfont, SPR001, Placebo
Spruce Biosciences
Polycystic Ovary Syndrome
08/23
08/23
NCT04457336 / 2019-004764-22: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Terminated
2
96
Europe, Canada, US, RoW
Tildacerfont/Placebo, SPR001
Spruce Biosciences, Spruce Biosciences, Inc.
Congenital Adrenal Hyperplasia
02/24
05/24
NCT05128942: A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH

Terminated
2
65
US
Tildacerfont, SPR001
Spruce Biosciences
Congenital Adrenal Hyperplasia, 21-OHD
01/25
01/25
NCT04544410 / 2019-004765-40: A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Terminated
2
100
Europe, Canada, US, RoW
Tildacerfont/Placebo, SPR001
Spruce Biosciences, Spruce Biosciences, Inc.
Congenital Adrenal Hyperplasia
06/24
01/25
JNJ-5939 / J&J
DUPLEX-AD, NCT06881251: A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Recruiting
2
240
Europe, Canada, Japan, US, RoW
Dupilumab, JNJ-95475939, Placebo
Janssen Research & Development, LLC
Dermatitis, Atopic
07/26
07/26
NCT05859724: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Terminated
1
126
Europe, Canada, US
NM26-2198, Placebo
Yellow Jersey Therapeutics AG, Kaken Pharmaceutical Co., Ltd.
Atopic Dermatitis
10/24
10/24
NexoBrid (bromelain) / MediWound, Kaken Pharma, Teva
NCT04468139: The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19

Recruiting
4
60
RoW
Quercetin, bromelain, Zinc, Vitamin C
Ministry of Health, Saudi Arabia
Covid-19
07/20
07/20
NCT04669119: Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.

Recruiting
4
120
Europe
Bromelain/Boswellia Serrata Casperome, Centella Asiatica/Vitamins, Placebo
University of Bari Aldo Moro
Breast Cancer Female, Pain, Postoperative
12/21
01/22
2020-003154-80: Study of the mechanism of action of a medicinal product based on Bromelain, Trypsin and Rutoside, compared to the same medicinal product without active ingredient called Placebo in subjects suffering from osteoarthritis. Étude du mécanisme d'action d'un médicament à base de Broméline, de Trypsine et de Rutoside, comparé au même médicament sans ingrédient actif appelé Placebo chez des sujets souffrant d'arthrose.

Not yet recruiting
4
40
Europe
Wobenzym, Gastro-resistant tablet, WOBENZYM®, enteric-coated tablet
Mucos Pharma GmbH & Co. KG, Mucos Pharma GmbH & Co. KG
Subjects suffering from knee Osteoarthitis Sujets souffrant d'Arthrose du genou, Subjects suffering from knee osteoarthritis Sujets souffrant d'arthrose du genou, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2005-002369-35: Reduction of pain under pressure of an experimentally induced hematoma in healthy volunteers by two Bromelain preparations (Bromelain-POS(R) and Traumanase(R) forte).

Ongoing
3
68
Europe
Bromelain-POS(R), Traumanase(R) forte, Bromelain-POS(R), Traumanase(R) forte, Bromelain-POS(R), Traumanase(R) forte
Ursapharm Arzneimittel GmbH&Co. KG
healthy subjects
 
 
NCT02278718 / 2014-003066-24: A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Completed
3
145
Europe, US, RoW
NexoBrid, Standard of Care
MediWound Ltd
Thermal Burns
04/21
12/22
NCT05681312: Evaluation of the Effect of Systemic Proteolytic Enzyme Therapy on Postoperative Inflammatory Response and QoL After Surgical Extraction of Impacted Mandibular Third Molars

Recruiting
3
55
RoW
systemic proteolytic enzyme (Tibrolin), tibrolin, Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg
University of Baghdad
Post Operative Pain
09/24
09/24
VALUE, NCT06568627: A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU

Recruiting
3
216
US
EscharEx (EX-03), EX-03, Placebo (Gel vehicle), Gel vehicle
MediWound Ltd
Venous Leg Ulcer (VLU)
12/26
03/27
2020-005523-37: A prospective controlled proof-of-concept trial to demonstrate anti-viral effects of oral bromelaine in COVID-19 positive patients

Ongoing
2
150
Europe
Gastro-resistant tablet, Bromelaintabletten hysan, 500 F.I.P.-Einheiten, magensaftresistente Tabletten
URSAPHARM Arzneimittel GmbH, URSAPHARM Arzneimittel GmbH
Diagnosis of SARS-CoV-2 infection documented by a positive PCR test, Diagnosis of SARS-CoV-2 infection documented by a positive PCR test, Diseases [C] - Virus Diseases [C02]
 
 
NCT05349929: Analgesic Effect of Anahil and Ibuprofen on Pain After Root Canal Therapy in Patients With Pulpitis of the Molars in Qazvin(a City in Iran)

Not yet recruiting
2
72
NA
Gelofen (generic name of Ibuprofen in Iran), Anahil ( generic name of Bromelain in Iran), Root Canal Therapy
Qazvin University Of Medical Sciences
Irreversible Pulpitis
11/22
12/22
NCT03976973: BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Not yet recruiting
2
62
NA
Bromelain, Acetylcysteine, Interventional radiology insertion of drain
Mucpharm Pty Ltd, Mercy Medical Center, Wake Forest University Health Sciences, University of Pittsburgh Medical Center, Catharina Ziekenhuis Eindhoven, Hospital Universitario Reina Sofia de Cordoba
Pseudomyxoma Peritonei, Peritoneal Cancer, Mucinous Adenocarcinoma, Mucinous Tumor
11/23
02/24
PROSTA-Q, NCT04252625: Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

Terminated
2
10
US
Q-Urol, Placebo
University of Utah, Farr Labs, LLC
Prostate Adenocarcinoma
12/23
01/24
VLU, NCT06690177: Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Not yet recruiting
2
45
Europe, US
EscharEx (EX-03), Placebo (Gel vehicle)
MediWound Ltd
Venus Leg Ulcers
12/27
09/28
NCT06981767: Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus

Not yet recruiting
2
42
NA
Topical Bromelain, 0.1% topical triamcinolone acetonide, Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase
Cairo University
Oral Lichen Planus
05/26
06/26
NCT06993337: Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Recurrent Aphthous Stomatitis

Not yet recruiting
2
63
NA
35% Topical Bromelain in Orabase, 50% Topical Bromelain in Orabase, 0.1% Topical Triamcinolone Acetonide in Orabase
Cairo University
Recurrent Aphthous Stomatitis
05/26
06/26
ACTRN12620001209987p: Dose Determination and Safety Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in diarrhoea predominant Irritable Bowel Syndrome patients

Not yet recruiting
1/2
200
 
Anatara Lifesciences, Anatara Lifesciences
Irritable Bowel Syndrome - diarrhoea predominant
 
 
ACTRN12617001612303: Injection of Bromelain and Acetylcysteine in combination into recurrent mucinous tumour or pseudomyxoma peritonei: a phase I/II study

Recruiting
1/2
60
 
Professor David Morris , Department of Surgery, St George Hospital, MUCPharm Pty Ltd
pseudomyxoma peritonei, recurrent pseudomyxoma peritonei , peritoneal disease , low grade appendix tumour
 
 
ACTRN12620001209987: Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in Irritable Bowel Syndrome patients

Recruiting
1/2
200
 
Anatara Lifesciences, Anatara Lifesciences
Irritable Bowel Syndrome
 
 
NCT05258682: Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Not yet recruiting
1/2
30
NA
Bromelains, Bromelain, Acetylcysteine, N-Acetylcysteine
Mucpharm Pty Ltd, St George Hospital, Australia
COVID-19 Pneumonia, COVID-19, Ventilator Associated Pneumonia, COVID-19 Acute Respiratory Distress Syndrome
09/22
10/22
NCT05000983: A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Recruiting
1/2
25
Canada
PluroGel, Standard dressing
University of Manitoba, Medline Industries
Burns
11/26
12/27
NCT04893863: A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Recruiting
1/2
20
Canada
Standard dressing, PluroGel
University of Manitoba
Burns
12/26
06/27
ACTRN12622000022763p: Safety of nebulised delivery of BromAc® (Bromelain & Acetylcysteine) in healthy volunteers: a potential treatment for severe COVID-19

Not yet recruiting
1
12
 
Mucpharm Pty Ltd , Mucpharm Pty Ltd
COVID-19
 
 
ACTRN12620000788976: Safety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 COVID-19 patients

Recruiting
1
40
 
Mucpharm Pty Ltd, Mucpharm Pty Ltd
SARS-CoV-2, COVID19
 
 
NCT04982146: Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Active, not recruiting
1
10
Europe
Bromelin, N-Acetylcysteine
Maimónides Biomedical Research Institute of Córdoba
Pseudomyxoma Peritonei
05/22
05/23
ACTRN12622000022763: Safety of nebulised delivery of BromAc® (Bromelain & Acetylcysteine) in healthy volunteers: a potential treatment for severe COVID-19

Completed
1
12
 
Mucpharm Pty Ltd , Mucpharm Pty Ltd
COVID-19
 
 
NCT05687760: Effect of Bromelain Versus Calcium Hydroxide as an Intracanal Medication on the Intensity of Postoperative Pain and Bacterial Load Reduction in Necrotic Single Rooted Lower Premolars

Not yet recruiting
1
30
NA
bromelain, Calcium hydroxide
Cairo University
Intracanal Medication, Bromelain, Calcium Hydroxide, Bacterial Load Reduction
02/23
02/23
NCT06775392: Comparative Evaluation of Bromelain-Quercetin Gel With Chlorhexidine Gel as Subgingival Local Drug Delivery Following Scaling and Root Planing In Stage I /II and Grade B Periodontitis - Randomized Control Clinical Trail

Completed
1
30
RoW
bromelain-quercetin gel, chlorhexidine gel, SRP
Krishnadevaraya College of Dental Sciences & Hospital
Periodontal Pocket
08/24
08/24
NCT06505759: Evaluation of 2%Bromelain Gel With 0.2%CHX Gel as Subgingival LDD Following SRP in Stage II/III and Grade B Periodontitis -A RCT

Recruiting
1
36
RoW
Bromelain gel, chlorhexidine gel, SRP
Krishnadevaraya College of Dental Sciences & Hospital
Periodontal Pocket
07/25
07/25
NCT04040660: Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Approved for marketing
N/A
US
NexoBrid
MediWound Ltd
Thermal Burn
 
 
ChiCTR2000039327: Study on evidence-based evaluation and therapeutic mechanism of integrated Chinese and Western medicine for treatment of diabetic foot -- An evidence-based evaluation of The combination of Rubber Shengji Paste and compound bromelain to promote the healing of the exposed wound of diabetic foot tendon

Recruiting
N/A
360
 
Routine basic medical and surgical treatment ;For external use, compound bromelain + Rubber muscle cream ;Routine basic medical and surgical treatment ;Debridement adhesive dressing
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, National key research and development plan funding support
Diabetic foot
 
 
NCT05520411: Examining the Effectiveness of Digestive Enzymes at Reducing Bloating and Stomach Distension

Completed
N/A
25
US
HUM Flatter Me
HUM Nutrition, Inc., Citruslabs
Stomach Distended, Bloating
01/23
01/23
AАBA, NCT06142994: Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting

Completed
N/A
310
Europe
Atusin CAP, Placebo
Neopharm Bulgaria Ltd.
Acute Bronchitis
06/24
06/24
NCT06516744: A Single Group Study to Evaluate the Efficacy of Bye Bye Bloat Capsules in Relieving Bloating and Promoting Healthy Digestion.

Completed
N/A
40
US
Bye Bye Bloat Capsules
Love Wellness, Citruslabs
Digestive Health, Digestion
04/24
04/24
NCT06351696: The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

Recruiting
N/A
84
RoW
Bromlein, Placebo
National Nutrition and Food Technology Institute
Ulcerative Colitis, Primary Sclerosing Cholangitis
07/24
08/24
NCT05879406: A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne

Completed
N/A
40
US
VitaMedica® Clear Skin Formula capsules, Placebo Capsules
Ablon Skin Institute Research Center, Grove Acquisition Subsidiary dba VitaMedica
Non-Cystic Acne
01/24
01/24
NCT06363721: A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental Health

Recruiting
N/A
18
US
PerioPull™
Designs for Health
Oral Health
07/25
08/25
NCT06298383: The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain

Recruiting
N/A
120
RoW
Trypsin, Bromelain and Rutoside, Flamogen, Diclofenac Potassium, Cataflam, Prednisolone Oral Tablet, solupred, Placebo
Cairo University, Egyptian Russian University
Symptomatic Irreversible Pulpitis
08/25
10/25
ACTRN12617000207314: “Quercetin as an augmentation agent in Treatment Resistant Schizophrenia”

Recruiting
N/A
20
 
University of Western Australia School of Medicine and Pharmacology, Graylands Hospital, University of Western Australia, Bioceuticals
schizophrenia
 
 
ACTRN12622000520730: A pilot study assessing the feasibility of NexoBrid versus the current standard of care of isolated upper limb burns: A solution to “the perfect crime”?

Terminated
N/A
20
 
Royal Brisbane and Women's Hospital, RBWH Foundation Burns Research Grant 2022
Burns
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fyarro (nanoparticle albumin-bound rapamycin) / Kaken Pharma
NCT03463265: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Completed
2
62
US
nab-sirolimus, nab-sirolimus + temozolomide, temozolomide, nab-sirolimus + bevacizumab, bevacizumab, nab-sirolimus + lomustine, lomustine (CCNU), nab-sirolimus + marizomib (MRZ), marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy, radiation
Aadi Bioscience, Inc.
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
08/22
08/22
NARETO, NCT06494150: Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Recruiting
2
37
US
nab-Sirolimus, Fyarro, Fulvestrant, Faslodex
University of Oklahoma, Aadi Bioscience, Inc.
Low Grade Ovarian Serous Adenocarcinoma
08/27
09/29
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
EEC-201, NCT05997017: Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Recruiting
2
29
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
03/25
10/26
NET-202, NCT05997056: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting
2
21
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
05/25
12/25
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Terminated
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
07/24
NCT02975882: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Completed
1
33
US
Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus Albumin-bound Nanoparticles, ABI 009, ABI-009, ABI009, Albumin-bound Sirolimus, Fyarro, Nab-Rapamycin, Nab-sirolimus, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Sirolimus, Sirolimus Albumin-bound Particles, Sirolimus Protein-bound Particles, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
03/22
12/24
RaSuRE, NCT03646240: ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy

Completed
1
14
US
ABI-009
Seattle Children's Hospital, Aadi Bioscience, Inc.
Epilepsy Intractable
08/22
12/22
NCT05661461: Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Recruiting
1
28
US
nab-sirolimus, ABI-009, nab-rapamycin, albumin-bound rapamycin
Aadi Bioscience, Inc.
Tumor, Solid, Tumor, Advanced Solid Tumor
04/25
04/25
NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Recruiting
1
12
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus
M.D. Anderson Cancer Center, Aadi Bioscience
Leiomyosarcoma, Soft-tissue Sarcomas
02/29
02/31
KRYSTAL -19, NCT05840510: Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Terminated
1
6
US
Adagrasib, MRTX849, Krazati, nab-Sirolimus, ABI -009, Fyarro
Mirati Therapeutics Inc., Aadi Bioscience, Inc.
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
12/24
12/24
Resunab (lenabasum) / Corbus Pharma, Kaken Pharma
ACTRN12620000712909: A Study of the Pharmacokinetics and Safety of a Single Dose of Lenabasum in Subjects with Hepatic Impairment Compared with Matched Healthy Controls

Not yet recruiting
1
32
 
Corbus Pharmaceuticals Inc, Corbus Pharmaceuticals
Hepatic impairment, Liver cirrhosis
 
 
Livdelzi (seladelpar) / Gilead
2020-005198-29: A study to evaluate the safety and tolerability of seladelpar in subjectswith primary biliary cholangitis

Ongoing
3/4
500
Europe, RoW
Seladelpar, MBX-8025, Capsule, hard
CymaBay Therapeutics, Inc., CymaBay Therapeutics, Inc.
Primary Biliary Cholangitis, A long-term liver disease in which the bile ducts in the liver becomedamaged. This gradually leads to a build-up of bile in the liver, which candamage it and eventually lead to scarring., Body processes [G] - Immune system processes [G12]
 
 
RESPONSE, NCT04620733 / 2020-004348-27: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Completed
3
193
Europe, Canada, US, RoW
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
CymaBay Therapeutics, Inc.
Primary Biliary Cholangitis
08/23
08/23
NCT03301506 / 2017-003910-16: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
500
Europe, Canada, US, RoW
Seladelpar 5 mg Capsule, MBX-8025, Livdelzi®, Seladelpar 10 mg Capsule
Gilead Sciences
Primary Biliary Cirrhosis
11/28
11/28
IDEAL, NCT06060665: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
90
Canada, US
Seladelpar 10 mg, Placebo
Gilead Sciences
Primary Biliary Cholangitis
06/26
06/26
AFFIRM, NCT06051617: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Recruiting
3
318
Canada, US, RoW
Seladelpar, Livdelzi®, Placebo
Gilead Sciences
Primary Biliary Cholangitis
08/30
08/30
2019-001760-30: The aim of this study is to assess the safety, tolerability and efficacy of seladelpar in subjects with Primary Sclerosing Cholangitis (PSC)

Not yet recruiting
2
100
Europe
Seladelpar, MBX-8025, Capsule
CymaBay Therapeutics, CymaBay Therapeutics
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease that is characterized by diffuse inflammation and fibrosis of the bile ducts. The intra and/or extrahepatic bile ducts can be affected with ongoing ductal destruction leading to cholestasis, advanced fibrosis, and cirrhosis. Disease progression will eventually lead to liver failure with its consequent complications such as portal hypertension and increased risk of malignancy, including HCC and cholangiocarcinoma., Disease of the liver, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04950764: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Completed
1
24
Europe, US, RoW
Seladelpar 10 mg, Livdelzi®, Seladelpar 10 mg or less
Gilead Sciences
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
02/25
02/25
Ekterly (sebetralstat) / KalVista
KONFIDENT, NCT05259917 / 2021-001226-21: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Completed
3
136
Europe, Canada, Japan, US, RoW
Placebo, KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
12/23
12/23
KONFIDENT-KID, NCT06467084: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Recruiting
3
36
Europe, Canada, Japan, US, RoW
KVD900 75 mg, KVD900 150 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
08/27
08/27
NCT05511922: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting
3
12
Europe, Canada, Japan, US, RoW
KVD900 600 mg, Drug: KVD900 300 mg
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
06/26
06/26
KONFIDENT-S, NCT05505916 / 2021-001176-42: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Active, not recruiting
3
145
Europe, Canada, Japan, US, RoW
KVD900 600 mg, KVD900 300 mg
KalVista Pharmaceuticals, Ltd., KalVista Pharmaceuticals Ltd
Hereditary Angioedema
06/26
06/26
NCT06628713: Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Available
N/A
US
Sebetralstat, KVD900
KalVista Pharmaceuticals, Ltd.
Hereditary Angioedema
 
 
tildacerfont (SPR001) / Spruce Biosciences
NCT05370521: A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Completed
2
27
US
Tildacerfont, SPR001, Placebo
Spruce Biosciences
Polycystic Ovary Syndrome
08/23
08/23
NCT04457336 / 2019-004764-22: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Terminated
2
96
Europe, Canada, US, RoW
Tildacerfont/Placebo, SPR001
Spruce Biosciences, Spruce Biosciences, Inc.
Congenital Adrenal Hyperplasia
02/24
05/24
NCT05128942: A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH

Terminated
2
65
US
Tildacerfont, SPR001
Spruce Biosciences
Congenital Adrenal Hyperplasia, 21-OHD
01/25
01/25
NCT04544410 / 2019-004765-40: A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Terminated
2
100
Europe, Canada, US, RoW
Tildacerfont/Placebo, SPR001
Spruce Biosciences, Spruce Biosciences, Inc.
Congenital Adrenal Hyperplasia
06/24
01/25
JNJ-5939 / J&J
DUPLEX-AD, NCT06881251: A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Recruiting
2
240
Europe, Canada, Japan, US, RoW
Dupilumab, JNJ-95475939, Placebo
Janssen Research & Development, LLC
Dermatitis, Atopic
07/26
07/26
NCT05859724: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Terminated
1
126
Europe, Canada, US
NM26-2198, Placebo
Yellow Jersey Therapeutics AG, Kaken Pharmaceutical Co., Ltd.
Atopic Dermatitis
10/24
10/24
NexoBrid (bromelain) / MediWound, Kaken Pharma, Teva
NCT04468139: The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19

Recruiting
4
60
RoW
Quercetin, bromelain, Zinc, Vitamin C
Ministry of Health, Saudi Arabia
Covid-19
07/20
07/20
NCT04669119: Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.

Recruiting
4
120
Europe
Bromelain/Boswellia Serrata Casperome, Centella Asiatica/Vitamins, Placebo
University of Bari Aldo Moro
Breast Cancer Female, Pain, Postoperative
12/21
01/22
2020-003154-80: Study of the mechanism of action of a medicinal product based on Bromelain, Trypsin and Rutoside, compared to the same medicinal product without active ingredient called Placebo in subjects suffering from osteoarthritis. Étude du mécanisme d'action d'un médicament à base de Broméline, de Trypsine et de Rutoside, comparé au même médicament sans ingrédient actif appelé Placebo chez des sujets souffrant d'arthrose.

Not yet recruiting
4
40
Europe
Wobenzym, Gastro-resistant tablet, WOBENZYM®, enteric-coated tablet
Mucos Pharma GmbH & Co. KG, Mucos Pharma GmbH & Co. KG
Subjects suffering from knee Osteoarthitis Sujets souffrant d'Arthrose du genou, Subjects suffering from knee osteoarthritis Sujets souffrant d'arthrose du genou, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2005-002369-35: Reduction of pain under pressure of an experimentally induced hematoma in healthy volunteers by two Bromelain preparations (Bromelain-POS(R) and Traumanase(R) forte).

Ongoing
3
68
Europe
Bromelain-POS(R), Traumanase(R) forte, Bromelain-POS(R), Traumanase(R) forte, Bromelain-POS(R), Traumanase(R) forte
Ursapharm Arzneimittel GmbH&Co. KG
healthy subjects
 
 
NCT02278718 / 2014-003066-24: A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Completed
3
145
Europe, US, RoW
NexoBrid, Standard of Care
MediWound Ltd
Thermal Burns
04/21
12/22
NCT05681312: Evaluation of the Effect of Systemic Proteolytic Enzyme Therapy on Postoperative Inflammatory Response and QoL After Surgical Extraction of Impacted Mandibular Third Molars

Recruiting
3
55
RoW
systemic proteolytic enzyme (Tibrolin), tibrolin, Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg
University of Baghdad
Post Operative Pain
09/24
09/24
VALUE, NCT06568627: A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU

Recruiting
3
216
US
EscharEx (EX-03), EX-03, Placebo (Gel vehicle), Gel vehicle
MediWound Ltd
Venous Leg Ulcer (VLU)
12/26
03/27
2020-005523-37: A prospective controlled proof-of-concept trial to demonstrate anti-viral effects of oral bromelaine in COVID-19 positive patients

Ongoing
2
150
Europe
Gastro-resistant tablet, Bromelaintabletten hysan, 500 F.I.P.-Einheiten, magensaftresistente Tabletten
URSAPHARM Arzneimittel GmbH, URSAPHARM Arzneimittel GmbH
Diagnosis of SARS-CoV-2 infection documented by a positive PCR test, Diagnosis of SARS-CoV-2 infection documented by a positive PCR test, Diseases [C] - Virus Diseases [C02]
 
 
NCT05349929: Analgesic Effect of Anahil and Ibuprofen on Pain After Root Canal Therapy in Patients With Pulpitis of the Molars in Qazvin(a City in Iran)

Not yet recruiting
2
72
NA
Gelofen (generic name of Ibuprofen in Iran), Anahil ( generic name of Bromelain in Iran), Root Canal Therapy
Qazvin University Of Medical Sciences
Irreversible Pulpitis
11/22
12/22
NCT03976973: BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Not yet recruiting
2
62
NA
Bromelain, Acetylcysteine, Interventional radiology insertion of drain
Mucpharm Pty Ltd, Mercy Medical Center, Wake Forest University Health Sciences, University of Pittsburgh Medical Center, Catharina Ziekenhuis Eindhoven, Hospital Universitario Reina Sofia de Cordoba
Pseudomyxoma Peritonei, Peritoneal Cancer, Mucinous Adenocarcinoma, Mucinous Tumor
11/23
02/24
PROSTA-Q, NCT04252625: Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

Terminated
2
10
US
Q-Urol, Placebo
University of Utah, Farr Labs, LLC
Prostate Adenocarcinoma
12/23
01/24
VLU, NCT06690177: Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Not yet recruiting
2
45
Europe, US
EscharEx (EX-03), Placebo (Gel vehicle)
MediWound Ltd
Venus Leg Ulcers
12/27
09/28
NCT06981767: Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus

Not yet recruiting
2
42
NA
Topical Bromelain, 0.1% topical triamcinolone acetonide, Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase
Cairo University
Oral Lichen Planus
05/26
06/26
NCT06993337: Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Recurrent Aphthous Stomatitis

Not yet recruiting
2
63
NA
35% Topical Bromelain in Orabase, 50% Topical Bromelain in Orabase, 0.1% Topical Triamcinolone Acetonide in Orabase
Cairo University
Recurrent Aphthous Stomatitis
05/26
06/26
ACTRN12620001209987p: Dose Determination and Safety Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in diarrhoea predominant Irritable Bowel Syndrome patients

Not yet recruiting
1/2
200
 
Anatara Lifesciences, Anatara Lifesciences
Irritable Bowel Syndrome - diarrhoea predominant
 
 
ACTRN12617001612303: Injection of Bromelain and Acetylcysteine in combination into recurrent mucinous tumour or pseudomyxoma peritonei: a phase I/II study

Recruiting
1/2
60
 
Professor David Morris , Department of Surgery, St George Hospital, MUCPharm Pty Ltd
pseudomyxoma peritonei, recurrent pseudomyxoma peritonei , peritoneal disease , low grade appendix tumour
 
 
ACTRN12620001209987: Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in Irritable Bowel Syndrome patients

Recruiting
1/2
200
 
Anatara Lifesciences, Anatara Lifesciences
Irritable Bowel Syndrome
 
 
NCT05258682: Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Not yet recruiting
1/2
30
NA
Bromelains, Bromelain, Acetylcysteine, N-Acetylcysteine
Mucpharm Pty Ltd, St George Hospital, Australia
COVID-19 Pneumonia, COVID-19, Ventilator Associated Pneumonia, COVID-19 Acute Respiratory Distress Syndrome
09/22
10/22
NCT05000983: A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Recruiting
1/2
25
Canada
PluroGel, Standard dressing
University of Manitoba, Medline Industries
Burns
11/26
12/27
NCT04893863: A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Recruiting
1/2
20
Canada
Standard dressing, PluroGel
University of Manitoba
Burns
12/26
06/27
ACTRN12622000022763p: Safety of nebulised delivery of BromAc® (Bromelain & Acetylcysteine) in healthy volunteers: a potential treatment for severe COVID-19

Not yet recruiting
1
12
 
Mucpharm Pty Ltd , Mucpharm Pty Ltd
COVID-19
 
 
ACTRN12620000788976: Safety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 COVID-19 patients

Recruiting
1
40
 
Mucpharm Pty Ltd, Mucpharm Pty Ltd
SARS-CoV-2, COVID19
 
 
NCT04982146: Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Active, not recruiting
1
10
Europe
Bromelin, N-Acetylcysteine
Maimónides Biomedical Research Institute of Córdoba
Pseudomyxoma Peritonei
05/22
05/23
ACTRN12622000022763: Safety of nebulised delivery of BromAc® (Bromelain & Acetylcysteine) in healthy volunteers: a potential treatment for severe COVID-19

Completed
1
12
 
Mucpharm Pty Ltd , Mucpharm Pty Ltd
COVID-19
 
 
NCT05687760: Effect of Bromelain Versus Calcium Hydroxide as an Intracanal Medication on the Intensity of Postoperative Pain and Bacterial Load Reduction in Necrotic Single Rooted Lower Premolars

Not yet recruiting
1
30
NA
bromelain, Calcium hydroxide
Cairo University
Intracanal Medication, Bromelain, Calcium Hydroxide, Bacterial Load Reduction
02/23
02/23
NCT06775392: Comparative Evaluation of Bromelain-Quercetin Gel With Chlorhexidine Gel as Subgingival Local Drug Delivery Following Scaling and Root Planing In Stage I /II and Grade B Periodontitis - Randomized Control Clinical Trail

Completed
1
30
RoW
bromelain-quercetin gel, chlorhexidine gel, SRP
Krishnadevaraya College of Dental Sciences & Hospital
Periodontal Pocket
08/24
08/24
NCT06505759: Evaluation of 2%Bromelain Gel With 0.2%CHX Gel as Subgingival LDD Following SRP in Stage II/III and Grade B Periodontitis -A RCT

Recruiting
1
36
RoW
Bromelain gel, chlorhexidine gel, SRP
Krishnadevaraya College of Dental Sciences & Hospital
Periodontal Pocket
07/25
07/25
NCT04040660: Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Approved for marketing
N/A
US
NexoBrid
MediWound Ltd
Thermal Burn
 
 
ChiCTR2000039327: Study on evidence-based evaluation and therapeutic mechanism of integrated Chinese and Western medicine for treatment of diabetic foot -- An evidence-based evaluation of The combination of Rubber Shengji Paste and compound bromelain to promote the healing of the exposed wound of diabetic foot tendon

Recruiting
N/A
360
 
Routine basic medical and surgical treatment ;For external use, compound bromelain + Rubber muscle cream ;Routine basic medical and surgical treatment ;Debridement adhesive dressing
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, National key research and development plan funding support
Diabetic foot
 
 
NCT05520411: Examining the Effectiveness of Digestive Enzymes at Reducing Bloating and Stomach Distension

Completed
N/A
25
US
HUM Flatter Me
HUM Nutrition, Inc., Citruslabs
Stomach Distended, Bloating
01/23
01/23
AАBA, NCT06142994: Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting

Completed
N/A
310
Europe
Atusin CAP, Placebo
Neopharm Bulgaria Ltd.
Acute Bronchitis
06/24
06/24
NCT06516744: A Single Group Study to Evaluate the Efficacy of Bye Bye Bloat Capsules in Relieving Bloating and Promoting Healthy Digestion.

Completed
N/A
40
US
Bye Bye Bloat Capsules
Love Wellness, Citruslabs
Digestive Health, Digestion
04/24
04/24
NCT06351696: The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

Recruiting
N/A
84
RoW
Bromlein, Placebo
National Nutrition and Food Technology Institute
Ulcerative Colitis, Primary Sclerosing Cholangitis
07/24
08/24
NCT05879406: A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne

Completed
N/A
40
US
VitaMedica® Clear Skin Formula capsules, Placebo Capsules
Ablon Skin Institute Research Center, Grove Acquisition Subsidiary dba VitaMedica
Non-Cystic Acne
01/24
01/24
NCT06363721: A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental Health

Recruiting
N/A
18
US
PerioPull™
Designs for Health
Oral Health
07/25
08/25
NCT06298383: The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain

Recruiting
N/A
120
RoW
Trypsin, Bromelain and Rutoside, Flamogen, Diclofenac Potassium, Cataflam, Prednisolone Oral Tablet, solupred, Placebo
Cairo University, Egyptian Russian University
Symptomatic Irreversible Pulpitis
08/25
10/25
ACTRN12617000207314: “Quercetin as an augmentation agent in Treatment Resistant Schizophrenia”

Recruiting
N/A
20
 
University of Western Australia School of Medicine and Pharmacology, Graylands Hospital, University of Western Australia, Bioceuticals
schizophrenia
 
 
ACTRN12622000520730: A pilot study assessing the feasibility of NexoBrid versus the current standard of care of isolated upper limb burns: A solution to “the perfect crime”?

Terminated
N/A
20
 
Royal Brisbane and Women's Hospital, RBWH Foundation Burns Research Grant 2022
Burns
 
 

Download Options